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Aim. To determine the prevalence of anti-HCV and risk factors associated with HCV infection in Nigerians. Materials and Method.
Patients attending a general outpatient clinic were administered a structured questionnaire on the risk factors for HCV infection.
They were also tested for anti-HCV using a third generation enzyme-linked immunosorbent assay. Result.T h es e r o p r e v a l e n c eo f
anti-HCV was 4.7%. Among the risk factors evaluated, none was found to be signiﬁcantly associated with anti-HCV seropositivity.
Conclusion. The risk factors associated with HCV infection in Nigerian patients are obscure. This warrants further studies on the
epidemiology of this important cause of liver disease.
1.Introduction
Hepatitis C virus (HCV) infection continues to be a major
disease burden on the world. In 1999, the World Health
Organisation (WHO) estimated a worldwide prevalence of
a b o u t3 %w i t ht h ev i r u sa ﬀecting 170 million people world-
wide [1]. A more recent estimate puts the prevalence at 2.2%
corresponding to about 130 million HCV-positive persons
worldwide [2]. Because many countries lack data, this esti-
mate is based on weighted averages for regions rather than
individual countries.
In the industrialized countries, HCV accounts for 20%
of cases of acute hepatitis, 70% of cases of chronic hepatitis,
40%ofcasesofendstagecirrhosis,60%ofcasesofhepatocel-
lular carcinoma (HCC), and 30% of liver transplants [3, 4].
An estimated 27% of cirrhosis and 25% of hepatocellular
carcinoma worldwide occur in HCV-infected people [5].
The most eﬃcient transmission of HCV is through
large or repeated direct percutaneous exposure to blood (of
transfusion or transplantation from infectious donors and
injecting drug use) [6]. HCV is less eﬃciently transmitted
by single small-dose percutaneous exposure (e.g., accidental
needle sticks) [6, 7] or by mucosal exposures to blood or
serum-derived ﬂuids (e.g., birth to an infected mother and
sexual intercourse with an infected partner) [6, 8, 9]. The
high transmission rate through illicit intravenous drug use
(IVDU) explains why the prevalence of HCV among peo-
ple who acquired human immunodeﬁciency virus (HIV)
through IVDU reaches 90% [10].
The risk factors for HCV transmission in Nigeria have
not been properly characterized. Even in the western world
where some risk factors have been identiﬁed, recent studies
indicate that the global epidemiology of HCV has been
changing [11, 12]. This scenario has compounded eﬀorts
at developing strategies for HCV screening. This study was




This study was a cross-sectional seroprevalence study involv-
ing adult patients attending the General out-patient clinic
of the University of Nigeria Teaching Hospital, Ituku-Ozalla.
The study was approved by the Hospital Research Ethics
Committee, and the participants gave informed consent.2 Gastroenterology Research and Practice
Table 1: Anti-HCV serostatus of patients.
Group Anti-HCV positive (%) Anti-HCV negative (%) Total
Males 6 (3.3) 177 (96.7) 183
Females 11 (6.2) 166 (93.8) 177
Total 17 (4.7) 343 (95.3) 360
Table 2: Risk factors for HCV infection.




Relative risk Odds ratio χ2 P value
Blood transfusion 23 6 1.115 1.121 0.022 0.882
Uvulectomy 23 7 1.46 1.495 0.013 0.91
Tattooing 02 0.000 3.93 0.99 0.75
Multiple sexual partners 35 9 1.025 1.026 0.002 0.97
Sharing of toothbrush 47 8 1.033 1.035 0.004 0.95
Sharing of razor blades 5 101 1.000 1.000 0.000005 1.00
Sharing of shaving sticks 11 9 1.059 1.062 0.003 0.95
Injections from quacks 24 0 1.008 1.009 0.00013 0.99
Scariﬁcation markings 11 7 1.176 1.187 0.026 0.87
Occupational exposure 05 0.000 1.784 0.248 0.62
Intravenous drug use 00 —— — —
Patients who had symptoms and signs suggestive of liver
disease were excluded. Each participant was administered a
structured questionnaire containing the putative risk factors
for HCV transmission.
Venousblood(5mLs)wasobtainedfromtheparticipants
and tested for antibody to HCV (anti-HCV) using a third
generation enzyme-linked immunosorbent assay (ELISA)
manufactured by DRG International Inc., USA. This test kit
has a sensitivity of 95% and speciﬁcity of 97.5%.
The data was analyzed and the results expressed as
meansandproportions.Diﬀerencesbetweenmeansandpro-
portions were determined using student’s t-test and chi-
squared test, respectively. A P value of ≤0.05 was considered
statistically signiﬁcant.
3. Results
Three hundred and sixty (360) patients participated in the
study. They consisted of 183 males (50.8%) and 177 females
(49.2%). Their ages ranged between 19 years and 75 years
(mean = 36.4 ±9.4 years). Seventeen patients tested positive
for anti-HCV (4.7%). The mean age of the anti-HCV-
positive patients was 36.0 ± 8.1 years while the mean age
of the anti-HCV-negative patients was 36.8 ± 9.9y e a r s .T h e
diﬀerence between the means was not statistically signiﬁcant
(P = 0.9526). Table 1 illustrates the anti-HCV serostatus and
gender distribution of the patients. The putative risk factors
were marginally more frequent in the anti-HCV seropositive
patientscomparedtotheanti-HCV-negativegroup,butnone
reached statistical signiﬁcance (Table 2).
4. Discussion
The seroprevalence of anti-HCV in this study was 4.7%.
This ﬁnding is comparable to the results of similar studies
across the continent [13–21]. However, none of the putative
risk factors evaluated in this study showed any signiﬁcant
association with anti-HCV seropositivity.
Transfusion-associated HCV infection was a predomi-
nant worldwide risk before HCV testing became available. It
has been virtually eliminated in those countries that imple-
mented routine HCV testing of donors [22], but in others,
receipt of blood transfusion remains an important source
of infection. Some countries continue to use commercial
donors to supplement their blood supplies [23]. In Nigeria,
the low risk of transmission through blood transfusion may
be related to the low prevalence of HCV in the general
populace, coupled with the fact that Nigeria is successfully
implementing a national blood safety programme led by
Safe Blood for Africa Foundation (SBFA) to ﬁght the spread
of HIV/AIDS [24]. An estimated 3.6% of Nigerians are
living with HIV and AIDS [25], which translates into about
3.3 million people. HCV coinfection with hepatitis B virus
(HBV) and/or HIV has been described in some studies in
Nigeria [26, 27].
Certain high-risk behaviours and practices which are
prevalent in African societies have been shown to play
some role in Hepatitis B virus (HBV) transmission. These
include scariﬁcation marks, sharing of sharp body-piercing
instruments like razor blades, sharing of toothbrushes, and
instruments for native uvulectomies [28]. Uvulectomy is
practiced in Nigerian communities as treatment for sore
throat. It is usually carried out by local healers in very unhy-
gienic environments without any consideration for infection
control. The instruments used are not usually sterilized.
The procedure carries other risks like bleeding, anemia,
sepsis, and transmission of other pathogens including HIV
and HBV. Deaths have resulted from such procedures
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These high-risk behaviours and practices do not seem to
contribute signiﬁcantly to the spread of HCV. The reason for
this may also be related to the low prevalence of HCV in the
populations involved. Another reason is the fact that HBV is
approximately 10 times more infectious than HCV [30, 31].
The risk factors for HCV infection may be unidentiﬁed
in a signiﬁcant proportion of patients in many parts of the
world. In a study in Iran, the risk factors for infection could
not be identiﬁed in 20% of cases [32]. In other studies,
risk factors accounting for infection remain unknown in 10–
40% of patients with acute or chronic Hepatitis C [33, 34].
A study conducted recently at a Northern California Liver
centre between 2001 and 2008 showed that Asian-Americans
are more likely to present with unidentiﬁable risk exposure
[35]. The researchers concluded that the commonly known
risk factors for HCV may be more appropriate for risk
assessment for Caucasians and Hispanics but not for Asian-
Americans. These ﬁndings pose major implications for
developing strategies for HCV screening in our increasingly
culturally diverse population.
In conclusion, the seroprevalence of anti-HCV in a pop-
ulation of Nigerians attending a general out-patient clinic is
4.7%. The risk factors associated with anti-HCV seropositiv-
ity are largely obscure, and this calls for more studies into the
epidemiology of HCV infection in order to develop eﬀective
strategies for screening.
References
[1] W. H. O., “Global surveillance and control of hepatitis C.
Report of a WHO consultation organized in collaboration
with the Viral Hepatitis Prevention Board Antwerp, Belgium,”
Journal of Viral Hepatitis, vol. 6, pp. 35–47, 1999.
[2] Y. Hutin, M. E. Kitler, G. J. Dore et al., “Global burden of dis-
ease (GBD) for hepatitis C,” Journal of Clinical Pharmacology,
vol. 44, no. 1, pp. 20–29, 2004.
[3] J. P. Benhamou, J. Rodes, H. Alter et al., “EASL international
consensus conference on hepatitis C, Paris, 26-28 February
1999: consensus statement,” Journal of Hepatology, vol. 30, no.
5, pp. 956–961, 1999.
[4] “Consensus conference. Treatment of hepatitis C. guidelines,”
Gastroent´ erologie Clinique et Biologique, vol. 26, pp. B312–
B320, 2002.
[5] J. F. Perz, G. L. Armstrong, L. A. Farrington, Y. J. Hutin, and
B. P. Bell, “The contributions of hepatitis B virus and hepa-
titis C virus infections to cirrhosis and primary liver cancer
worldwide,” Journal of Hepatology, vol. 45, no. 4, pp. 529–538,
2006.
[6] “Recommendations for prevention and control of hepatitis
C virus (HCV) infection and HCV-related chronic disease.
Centre for disease control and prevention,” MMWR—Recom-
mendations and Reports, vol. 47, pp. 1–39, 1998.
[7] V. Puro, N. Petrosillo, and G. Ippolito, “Risk of hepatitis
C seroconversion after occupational exposure in healthcare
workers. Italian Study Group on occupational risk of HIV and
other bloodborne infections,” American Journal of Infection
Control, vol. 23, pp. 273–277, 1995.
[ 8 ]E .A .R o b e r t sa n dL .Y e u n g ,“ M a t e r n a l - i n f a n tt r a n s m i s s i o no f
hepatitis C virus infection,” Hepatology, vol. 36, no. 5, supple-
ment 1, pp. S106–S113, 2002.
[9] N. A. Terrault, “Sexual activity as a risk factor for hepatitis C,”
Hepatology, vol. 36, no. 5, supplement 1, pp. S99–S105, 2002.
[10] M. S. Sulkowski and D. L. Thomas, “Hepatitis C in the HIV-
infected person,” Annals of Internal Medicine, vol. 138, no. 3,
pp. 197–207, 2003.
[11] J. I. Esteban, S. Sauleda, and J. Quer, “The changing epidemi-
ology of hepatitis C virus infection in Europe,” Journal of
Hepatology, vol. 48, no. 1, pp. 148–162, 2008.
[12] P. Fabris, V. Baldo, T. Baldovin et al., “Changing epidemiology
of HCV and HBV infections in Northern Italy: a survey in
the general population,” Journal of Clinical Gastroenterology,
vol. 42, no. 5, pp. 527–532, 2008.
[13] M. Imoru, C. Eke, and A. Adegoke, “Prevalence of hepatitis B
surface antigen (HBsAg), hepatitis C virus (HCV) and human
immunodeﬁciency virus (HIV) among blood donors in Kano
State, Nigeria,” Journal of Medical Laboratory Science, vol. 12,
pp. 59–63, 2003.
[14] O. Erhabor, O. A. Ejele, and C. A. Nwauche, “The risk of
transfusion-acquired hepatitis-C virus infection among blood
donors in Port Harcourt: the question of blood safety in
Nigeria,” Nigerian Journal of Clinical Practice, vol. 9, no. 1,
pp. 18–21, 2006.
[15] B.B.D.Koate,F.I.Buseri,andZ.A.Jeremiah,“Seroprevalence
of hepatitis C virus among blood donors in Rivers State,
Nigeria,” Transfusion Medicine, vol. 15, no. 5, pp. 449–451,
2005.
[16] D. Z. Egah, B. M. Mandong, D. Iya et al., “Hepatitis C Virus
antibodies among blood donors in Jos, Nigeria,” Annals of
African Medicine, vol. 3, pp. 35–37, 2004.
[17] S. C. Nwokediuko, O. G. Ibegbulam, and T. Ugwu, “Hepatitis
C Virus seroprevalence in blood d onors at the University
of Nigeria Teaching Hospital Enugu,” Journal of College of
Medicine, vol. 12, pp. 85–88, 2007.
[ 1 8 ] Z .A .J e r e m i a h ,B .K o a t e ,F .B u s e ri ,a n dF .E m e l i k e ,“ P r ev a l e n c e




[19] O. Azeez-akande, A. Sarki, E. E. Wokedi, A. Olabode, and P.
Alabi, “Seroprevalence and risk factors of Hepatitis C virus in
patientsandblooddonorsinKano,Nigeria,”African Journal of
Clinical and Experimental Microbiology, vol. 11, pp. 170–173,
2010.
[20] C. I. Mboto, I. E. Andy, O. I. Eni, and A. P. Jewell, “Prevalence,
sociodemographic characteristics and risk factors for hepatitis
C infection among pregnant women in Calabar municipality,
Nigeria,” Hepatitis Monthly, vol. 10, no. 2, pp. 116–120, 2010.
[21] E. S. Amadi, C. E. Ononiwu, N. Aballa, S. A. Oladimeji, F.
A. Ancke, and C. O. Aneke, “The epidemiology of hepatitis
C virus infection among patients attending the federal dental
clinic, Enugu,” Trends in Medical Research, vol. 4, no. 4,
pp. 91–95, 2009.
[22] M. P. Busch, S. A. Glynn, S. L. Stramer et al., “A new strategy
for estimating risks of transfusion-transmitted viral infections
based on rates of detection of recently infected donors,”
Transfusion, vol. 45, no. 2, pp. 254–264, 2005.
[23] W. Hladik, P. Kataaha, J. Mermin et al., “Prevalence and
screening costs of hepatitis C virus among Ugandan blood
donors,” Tropical Medicine and International Health, vol. 11,
no. 6, pp. 951–954, 2006.
[24] “Safe Blood Programs-Nigeria,” 2011, http://www.safeblood-
international.org/.4 Gastroenterology Research and Practice
[25] UNGASS Country Report Nigeria, 2010.
[26] S. M. Agwale, L. Tanimoto, C. Womack et al., “Prevalence
of HCV coinfection in HIV-infected individuals in Nigeria
and characterization of HCV genotypes,” Journal of Clinical
Virology, vol. 31, supplement 1, pp. S3–S6, 2004.
[27] J. A. Otegbayo, B. O. Taiwo, T. S. Akingbola et al., “Prevalence
ofhepatitisBandCseropositivityinaNigeriancohortofHIV-
infected patients,” Annals of Hepatology, vol. 7, no. 2, pp. 152–
156, 2008.
[28] S.C.Nwokediuko, “Riskfactors forhepatitisBvirustransmis-
sion in Nigerians. A case-control study,” The Internet Journal
of Gastroenterology, vol. 10, no. 1, 2010.
[29] A. O. Olaosun, K. O. Ojemakinde, A. A. Raji, T. O. Adedeji,
and S. O. Adebola, “Death of a child with leukemia subjected
to uvulectomy,” The Internet Journal of Third World Medicine,
vol. 4, no. 2, 2007.
[30] C. Weinbaum, R. Lyeria, and H. S. Margolis, “Centre for dis-
ease control and prevention. Prevention and control of infec-
tions with hepatitis viruses in correctional settings. Centre for
disease control and prevention,” MMWR—Recommendations
and Reports, vol. 52, pp. 1–36, 2003.
[31] C. Weinbaum, I. Williams, and E. E. Mast, “Centre for disease
control and prevention. Recommendations for identiﬁcation
and public health management of persons with chronic
hepatitis B virus infection,” MMWR—Recommendations and
Reports, vol. 57, pp. 1–20, 2008.
[32] S. M. Alavian, B. Gholami, and S. Masarrat, “Hepatitis C
risk factors in Iranian volunteer blood donors: a case-control
study,” Journal of Gastroenterology and Hepatology, vol. 17, no.
10, pp. 1092–1097, 2002.
[33] S. Zeuzem, G. Teuber, J. H. Lee, B. R¨ uster, and W. Kurt Roth,
“Risk factors for the transmission of hepatitis C,” Journal of
Hepatology, vol. 24, no. 2, pp. 3–10, 1996.
[34] R. A. Pond´ e, “Hidden hazards of HCV transmission,” Medical
Microbiology and Immunology, vol. 200, no. 1, pp. 7–11, 2011.
[35] E. Y. Ho, N. B. Ha, H. Mindie, and H. Nguyen, “Risk factors
for Hepatis C acquisition are more likely to be unidentiﬁable
in Asian-Americans compared to Caucasians or Hispanics
(prospective study),” in Proceedings of the Digestive Disease
Week (DDW ’09), Chicago, Ill, USA, May 2009, abstract
M1779.